AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), is committed to delivering top-tier services to clients and partners worldwide. With expertise in developing and manufacturing a wide range of therapeutic proteins and genetic materials, AGC Biologics operates in key locations across the U.S., Europe, and Asia. As part of AGC Inc.
‘s Life Science Business, AGC Biologics plays a crucial role in advancing biopharmaceuticals and other key areas of the industry. In a recent development, AGC Biologics announced a significant partnership with specialty vaccine company Valneva SE for the supply of drug substance for a groundbreaking Shigella bioconjugate vaccine. This partnership highlights AGC Biologics’ capabilities in handling complex molecules and multi-valent assets, positioning the company as a key player in the global fight against infectious diseases.
Read more from finance.yahoo.com